Your browser is no longer supported. Please, upgrade your browser.
GeoVax Labs, Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own8.31% Shs Outstand6.32M Perf Week-0.25%
Market Cap26.84M Forward P/E- EPS next Y-1.27 Insider Trans0.00% Shs Float5.80M Perf Month-5.02%
Income-4.80M PEG- EPS next Q-0.37 Inst Own7.90% Short Float7.46% Perf Quarter-13.88%
Sales0.90M P/S29.82 EPS this Y99.70% Inst Trans- Short Ratio0.16 Perf Half Y-17.29%
Book/sh3.08 P/B1.29 EPS next Y-0.80% ROA-30.30% Target Price- Perf Year18.86%
Cash/sh2.88 P/C1.38 EPS next 5Y- ROE-31.80% 52W Range2.56 - 8.71 Perf YTD17.46%
Dividend- P/FCF- EPS past 5Y- ROI-29.00% 52W High-54.42% Beta1.93
Dividend %- Quick Ratio54.80 Sales past 5Y33.60% Gross Margin- 52W Low55.08% ATR0.26
Employees8 Current Ratio54.80 Sales Q/Q-75.00% Oper. Margin- RSI (14)42.71 Volatility6.21% 6.15%
OptionableNo Debt/Eq0.00 EPS Q/Q68.40% Profit Margin- Rel Volume0.06 Prev Close4.00
ShortableYes LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume2.76M Price3.97
Recom- SMA20-3.50% SMA50-13.29% SMA200-19.73% Volume174,735 Change-0.75%
Nov-19-20Initiated Maxim Group Buy $8
Oct-18-21 09:00AM  
Oct-14-21 09:00AM  
Sep-30-21 10:18AM  
Sep-29-21 12:09PM  
Sep-28-21 04:00PM  
Sep-07-21 09:00AM  
Aug-20-21 02:42PM  
Aug-19-21 04:00PM  
Aug-17-21 08:42AM  
Aug-16-21 08:30AM  
Aug-12-21 09:00AM  
Aug-11-21 04:00PM  
Aug-04-21 09:00AM  
Jul-22-21 09:00AM  
Jul-07-21 09:00AM  
Jun-10-21 11:00AM  
Jun-07-21 09:00AM  
May-11-21 01:08PM  
May-06-21 04:00PM  
Apr-26-21 09:00AM  
Apr-20-21 10:51AM  
Apr-08-21 10:25AM  
Apr-01-21 09:00AM  
Mar-23-21 04:30PM  
Mar-17-21 09:00AM  
Mar-15-21 09:00AM  
Mar-10-21 09:00AM  
Mar-04-21 09:55AM  
Mar-03-21 09:00AM  
Mar-01-21 09:00AM  
Feb-18-21 03:20AM  
Feb-11-21 02:00PM  
Feb-08-21 11:43PM  
Jan-11-21 09:00AM  
Jan-05-21 09:00AM  
Nov-30-20 09:00AM  
Nov-05-20 05:00PM  
Oct-30-20 10:08AM  
Oct-28-20 09:00AM  
Oct-26-20 10:49AM  
Sep-29-20 02:00PM  
Sep-24-20 09:23PM  
Sep-15-20 09:00AM  
Sep-03-20 09:42AM  
Aug-26-20 09:00AM  
Aug-24-20 09:00AM  
Aug-13-20 09:00AM  
Aug-10-20 09:00AM  
Jul-09-20 11:42AM  
Jun-29-20 09:00AM  
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.